ArticleCancer prevention research (Philadelphia, Pa.)2011
Rapamycin and mTORC1 inhibition in the mouse: skin cancer prevention.
Article in Cancer prevention research (Philadelphia, Pa.), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 27 citations in OpenAlex.
- 5'-Cap‒Dependent Translation as a Potent Therapeutic Target for Lethal Human Squamous Cell Carcinoma.The Journal of investigative dermatology · 2021Article
- Combined mTORC1/mTORC2 inhibition blocks growth and induces catastrophic macropinocytosis in cancer cells.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- Review
- Translating Mechanism-Based Strategies to Break the Obesity-Cancer Link: A Narrative Review.Journal of the Academy of Nutrition and Dietetics · 2018Review
- A weighty problem: metabolic perturbations and the obesity-cancer link.Hormone molecular biology and clinical investigation · 2015Review
- Effect of Metformin, Rapamycin, and Their Combination on Growth and Progression of Prostate Tumors in HiMyc Mice.Cancer prevention research (Philadelphia, Pa.) · 2015Article
- Reduction behavior induced by HL010183, a metformin derivative against the growth of cutaneous squamous cell carcinoma.International journal of clinical and experimental pathology · 2015Article
- Tumor promoter-induced cellular senescence: cell cycle arrest followed by geroconversion.Oncotarget · 2014Article
- AZD1480 delays tumor growth in a melanoma model while enhancing the suppressive activity of myeloid-derived suppressor cells.Oncotarget · 2014Article
- PI3K-AKT signaling is a downstream effector of retinoid prevention of murine basal cell carcinogenesis.Cancer prevention research (Philadelphia, Pa.) · 2014Article
- Interacting inflammatory and growth factor signals underlie the obesity-cancer link.The Journal of nutrition · 2014Review
- Immunosuppressants in cancer prevention and therapy.Oncoimmunology · 2013Review
- Selective anti-cancer agents as anti-aging drugs.Cancer biology & therapy · 2013Article
- Hsp90 inhibitors and drug resistance in cancer: the potential benefits of combination therapies of Hsp90 inhibitors and other anti-cancer drugs.Biochemical pharmacology · 2012Review
- Metformin, an antidiabetic agent reduces growth of cutaneous squamous cell carcinoma by targeting mTOR signaling pathway.Photochemistry and photobiologyArticle
Corrections and comments
- Comment on
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Therapeutic and preventive effects of rapamycin include reduced risk of nonmelanoma skin cancer (NMSC). In this issue of the journal (beginning on page 1011), Checkley and colleagues report that rapamycin inhibits mTOR complex 1 in murine epidermis, thereby inhibiting tumor promotion mediated by tetradecanoyl phorbol-13 acetate in association with a strong anti-inflammatory effect. Rapamycin is an immunosuppressive drug for preventing graft rejection in organ transplant recipients and reduces the risk of NMSC and Kaposi's sarcoma in this population, albeit by mechanisms distinct from immunosuppression. Important future directions include identifying molecular predictors of rapamycin/rapalog sensitivity or resistance (potentially, for example, PI3K pathway alterations and KRAS mutations) and combined non-rapalog, mTOR-targeting approaches, all of which should increase efficacy and minimize toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.